Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2018’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)

- The report reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Herpes Labialis (Oral Herpes) therapeutics and enlists all their major and minor projects

- The report assesses Herpes Labialis (Oral Herpes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AiCuris GmbH & Co KG

Beech Tree Labs Inc

NanoViricides Inc

Shulov Innovative Science Ltd

AiCuris GmbH & Co KG

Beech Tree Labs Inc

NanoViricides Inc

Shulov Innovative Science Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Herpes Labialis (Oral Herpes) - Overview

Herpes Labialis (Oral Herpes) - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Herpes Labialis (Oral Herpes) - Overview

Herpes Labialis (Oral Herpes) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Herpes Labialis (Oral Herpes) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development

AiCuris GmbH & Co KG

Beech Tree Labs Inc

NanoViricides Inc

Shulov Innovative Science Ltd

Herpes Labialis (Oral Herpes) - Drug Profiles

Aspidasept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-TMLHSV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ethamsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

herpes simplex virus [type 1, 2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pritelivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Herpes Labialis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Labialis (Oral Herpes) - Dormant Projects

Herpes Labialis (Oral Herpes) - Discontinued Products

Herpes Labialis (Oral Herpes) - Product Development Milestones

Featured News & Press Releases

Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes

Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial

Nov 05, 2010: AiCuris to Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress

Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial

Jul 07, 2010: Beech Tree Labs Wins FDA Approval For Oral Herpes IND Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2018

Number of Products under Development by Companies, H2 2018

Number ...

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Herpes Labialis (Oral Herpes) - Pipeline by AiCuris GmbH & Co KG, H2 2018

Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs Inc, H2 2018

Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, H2 2018

Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, H2 2018

Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2018

Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2018 7

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products by Targets, H2 2018 13

Number of Products by Stage and Targets, H2 2018 13

Number of Products by Mechanism of Actions, H2 2018 15

Number of Products by Stage and Mechanism of Actions, H2 2018 15

Number of Products by Routes of Administration, H2 2018 17

Number of Products by Stage and Routes of Administration, H2 2018 17

Number of Products by Molecule Types, H2 2018 19

Number of Products by Stage and Molecule Types, H2 2018 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports